# Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

> **NCT05156203** · PHASE1 · RECRUITING · sponsor: **Taivex Therapeutics Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** T-1301 Capsules

## Key facts

- **NCT ID:** NCT05156203
- **Lead sponsor:** Taivex Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-19
- **Primary completion:** 2027-01
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156203, "Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05156203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*